Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03742349
Title Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | ESP | AUS

Facility Status City State Zip Country Details
Columbia University Medical Center- New York Presbyterian Columbia New York New York 10032 United States Details
Sarah Cannon Research Institute Sarah Cannon Research Nashville Tennessee 37203 United States Details
Novartis Investigative Site Westmead New South Wales 2145 Australia Details
Novartis Investigative Site Shatin, New Territories Hong Kong Details
Novartis Investigative Site Tel Aviv 6423906 Israel Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Milano MI 20141 Italy Details
Novartis Investigative Site Kashiwa Chiba 277 8577 Japan Details
Novartis Investigative Site Amsterdam 1066 CX Netherlands Details
Novartis Investigative Site Singapore 119074 Singapore Details
Novartis Investigative Site Singapore 169610 Singapore Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Valencia Comunidad Valenciana 46010 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field